SLC5A5 expression was significantly lower in carcinomas than that in normal adjacent counterparts (Fig. 1). No significant difference was observed between the three different carcinoma histotypes (PTC, FTC and PDTC). Considering the analysis in DTC, SLC5A5 expression was significantly lower in males and in cases with vascular invasion (P = 0.003 and P = 0.03, respectively) (Table 1). SLC5A5 expression in normal thyroid from males was not significantly different from that of females (data not shown). In addition, there was a tendency to lower SLC5A5 levels in cases with extrathyroidal extension (P = 0.06) and in PTCs harboring BRAFV600E mutation (P = 0.07). When the statistical analysis was performed only in the PTC group, all the significant associations described in the DTC group were maintained. Figure 1SLC5A5 mRNA expression in thyroid carcinomas and paired normal adjacent counterparts. Table 1Associations between SLC5A5 mRNA expression with clinicopathological and molecular features in DTCs.SLC5A5 expressionP valueGenderF (n = 47)1.2 ± 2.2M (n = 12)0.2 ± 0.20.003Age<45 years (n = 30)1.0 ± 1.5≥45 years (n = 29)1.1 ± 2.40.8Tumor capsulePresent (n = 27)1.1 ± 1.6Absent (n = 30)0.7 ± 1.60.4Tumor capsule invasionYes (n = 17)0.9 ± 1.6No (n = 11)1.4 ± 1.40.4Extrathyroidal extensionYes (n = 17)0.5 ± 1.1No (n = 37)1.4 ± 2.40.06Lymphocytic infiltrationPresent (n = 19)0.9 ± 1.9Absent (n = 37)1.2 ± 2.20.7Vascular invasionPresent (n = 28)0.4 ± 0.8Absent (n = 29)1.5 ± 2.60.03Lymph node metastasesPresent (n = 13)0.5 ± 0.8Absent (n = 18)0.4 ± 0.70.8BRAF*WT n = (27)1.6 ± 2.7V600E (n = 20)0.5 ± 1.00.07NRASWT (n = 54)1.0 ± 2.0Mut (n = 6)1.3 ± 1.70.7*PTC only.